GenSight Biologics successfully raises €25 million in an oversubscribed private placement with US and European institutional investors

GenSight Biologics launches a capital increase of approximately €25 million by means of an accelerated bookbuilding process

BioEurope – Digital

4th Annual Gene Therapy for Rare Disorders Europe – Virtual

GenSight Biologics Reports Cash Position as of September 30, 2020 and Provides Operational Update

GenSight Biologics Appoints Elsy Boglioli to its Board of Directors

Cell & Gene Meeting on the Mesa – Virtual

HealthTech Innovation Days (HTID®), Paris, France & Virtual Conference

Chardan 4th Annual Genetic Medicines Conference – Virtual

GenSight Biologics Announces Publication of Meta-Analysis Confirming that Spontaneous Recovery in LHON is rare in the Journal of Neuro-Ophthalmology